Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bra...
Source: businessinsider.com
Berndt Modig News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Berndt Modig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Berndt Modig Today - Breaking & Trending Today
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting...
Source: businessinsider.com
Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant
By Denny Jacob Clinical-stage company Pharvaris said the U.S. Food and Drug Administration lifted the clinical hold on the investigational new drug...
Source: marketwatch.com
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 rece...
Source: businessinsider.com
Pharvaris Announces FDA Lifting of the Clinical Hold of
ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Source: globenewswire.com